Welcome. Good morning or good afternoon, depending on where you are. Today is April 12, 2023. My name is Lisa Crossley, and I'm the CEO at Reliq Health Technologies. Today, we'll be providing a webinar that is a corporate update. Really an update on our progress to date. That forward-looking statement disclaimer that I just whizzed past is something you should review and take all remarks in this webinar in that context. The agenda for today's webinar, I'll provide some operational updates. I'll revisit the outlook for 2023. We've received quite a few shareholder questions to the IR email or by phone, I will do my best to answer all of those. Lastly, I'll provide dates for our future webinars subsequent to this one. Operational updates are up first. As those of you who've been following this story for a while are aware, we had issues that we identified in late 2022 around two bottlenecks in our existing processes, and those were around adherence and collections. As of the beginning of this calendar year, we put in new plans and new processes to address these bottlenecks, and a large part of the purpose for today's webinar is to give you an update on how we've been making those improvements in our process since January. On the adherence front, by the end of this fiscal year, the company will be managing adherence for all new clients and the vast majority of existing clients. We're well on track in terms of our goal to be responsible for adherence for 100% of our client base. As you know, any new client is enrolled through a contract that includes provision where they must allow Reliq to manage adherence for them. With the existing clients, we are in the process of moving all of those clients onto a process where we or a new infrastructure, a structure where we manage all of the adherence for them. As part of that change, some of the changes we've made internally, we've updated the iUGO Care platform to provide timely alerts to care managers if a patient is at risk of non-adherence for a given month, so that we can intervene early now that we are able to take on adherence, responsibility for adherence. We are leveraging our interactive voice recognition technology or automated phone calls to provide daily reminders to any patients who are non-adherent. Our care managers can also call patients who need additional adherence support. Based on those automated alerts they're receiving through the platform, when they've identified a patient who is at risk of being non-adherent in a given month, if necessary, they can make that phone call and work through the issues with that patient. Our existing clients previously had adherence levels for their patient populations that were below 30%, as of the end of 2022 calendar year. We have taken over adherence for over 30% of those existing clients to date. We started that process in January. It is a gradual process, but we've really gathered a lot of momentum now. By the end of June, we expect that figure to be essentially 100% or very close. We will have taken over adherence for all of these patients, all of these clients, rather, by the end of this fiscal year, so end of June 2023. With the clients where we've already taken over the adherence, it's a substantial pool, statistically significant, we've increased their adherence to over 70% their patient's adherence. There's been a really substantial improvement in the adherence level in clients with patients of clients where we've taken over the responsibility for managing adherence. We are happy with that plan and that progress. This was our goal. I think we're well on our way to hit our target adherence, which is over 80% for all patients in any given month. The reason it's not ever going to be 100% is patients who are either traveling and don't wanna take their devices with them or who have been hospitalized or received some other form of acute intervention during a month will not be billable for their clinicians. The clinician can't provide the service if the patient is receiving an acute intervention like a hospitalization or even a home care visit. For those, that percentage of patients, they're not able to be adherent in a given month. We're trying to be conservative in our projections. Our target is over 80% adherence across all patients to allow for things like those acute interventions or, you know, travel, vacation for a given patient. Collections, we've made tremendous progress on collections. First, just to kind of clear up an issue or a question that we get from a lot of investors, that's the way that we kind of parse the receivables on our financial statements. This is really critical information in order for shareholders to genuinely understand where things are in terms of collections. On the financial statements on the balance sheet, you'll see three different categories for receivables. Under trade and other receivables, that's referring to payments that are due within the company's standard payment terms. For us, that's net 60 days. The current portion of long-term receivables, on the other hand, refers to payments that are expected within the next 12 months for any hardware, so those monitoring devices that was purchased on a 12- or 24-month payment plan. As you will hopefully recall, we sell hardware, on either 12- or 24-month payment plans, or clients can pay up front, but for the most part, they tend to choose the payment plans. That's to our benefit because we generate a much higher margin on those payment plans we do on an upfront sale. We have clients who are on a 12 or 24-month payment plan but have payments due within the next 12 months. Those payments are considered current portion of long-term receivables. The long-term receivables bucket, if you will, on the balance sheet refers to payments that are expected during the second 12 months of a 24-month payment plan. They're due within 12 to 24 months of the date of the financials for hardware that was purchased on a 24-month payment plan. That's why you'll see different amounts in those different buckets. What I think is sort of most meaningful is the first two buckets. Looking at trade and other receivables and current portion of long-term receivables gives you a good sense of the cash the company is expecting to collect in a relatively short timeframe. Collections, as you may recall from the January webinar, account managers have made collections their top priority since the beginning of January of this year. We now have all clients signed up for payment plans, and all clients have started making payments. We expect to be caught up on receivable collections by the end of June 2023. That really primarily refers to trade and other receivables and the current portion of long-term receivables, because the long-term receivables themselves are 12 to 24 months out. Those are payments that are not actually due now, and they're due in 12 to 24 months for the hardware that was purchased on a 24-month payment plan. The company's collected over $1 million in payments since January 1st. I really need to stress the majority of that collection took place in the last few weeks. It takes a little while to mobilize our clients, and we gave the account managers their sort of marching orders at the beginning of January to go out and enforce collections and get these payment plans put in place. When we really started receiving those payments has been in the last couple of weeks, and it's been really steadily picking up. While $1 million on its own may not sound that impressive, and you know, $1 million in three weeks is a pretty good run rate. As a means for comparison, the company collected a total of $2.5 million in payments in fiscal year 2021 and fiscal year 2022 combined. You know, in the last few weeks, we've collected a pretty good amount relative to what we collected in the preceding two years altogether. We collected about $200,000 in the first half of fiscal year 2023, we're now in the second half of fiscal year 2023. Obviously, collections have picked up substantially in the last few weeks, and that reflects our new focus on collections and the hard work that the account managers have been doing. Now that we have all of the clients on established payment plans to get them caught up, now that we can see that clients have started making those payments, we're very confident that we are going to collect over $1 million a month for the remainder of the fiscal year, and certainly more going forward beyond the end of the fiscal year. Reminder, our fiscal year ends June 30th, 2023. We expect to collect over $5 million for this fiscal year, 2023. Obviously, that rate of collections and the total collections will be much higher as we move forward, and as we see the impact of things like improving adherence, as well as obviously staying current on collections. The company expects to be profitable in Q4 of this fiscal year, so this current quarter, and certainly going forward. Our outlook for 2023, you know, certainly I'll sort of start off by saying we're going to have a much more comfortable cash position in the remainder of 2023 than we have the last few years. That's a very nice position for the company to be in. On a more granular level, as we discussed in previous webinars, I think, most recently in January, we have about $15 million in contracted hardware sales that were deferred from the last two quarters of 2022 to 2023. That was really around clients requesting that the company delay shipment of that hardware due to market conditions. When the capital markets are doing poorly, you know, a lot of the physicians looking at their portfolios will say, "I think I'm just gonna defer that large capital expense into the next year." As a result, the software revenue associated with that, those hardware orders was deferred, but we have started shipping that hardware, and we expect the majority of those hardware orders to be fulfilled by the end of the fiscal year. End of June 2023. You may recall that we recognize revenue for hardware when the client takes possession of the hardware. When they physically have it on-site, or in the patient's hands. Once we ship, essentially within a few days, that hardware is in the possession of that client and we are able to recognize the revenue. As soon as we ship, really are able to start getting this revenue onto the books. The hardware, as you know, is sold on the 12-24 month payment plans. We've already started receiving scheduled payments from the hardware that we've shipped to date, but those hardware shipments are really starting to pick up now. You know, we really spent the first quarter kind of making a lot of changes to our processes and helping clients get comfortable with some of those changes. Now we've gained a lot of momentum, and so things are starting to really pick up speed. We anticipate that we'll have all of that hardware shipped or close to all of it by the end of June. You'll really see that translate to the financial statements in the second half of the year as we start to collect payments for those hardware shipments. All hardware orders will also translate to subsequent software revenue. That's really important to remember that, you know, this hardware revenue is great, but it's also just a fraction of what we anticipate the software revenue for a given client will be. It's a really good leading indicator of future recurring software revenue. Obviously it has value on its own as well as hardware revenue. Payment for those, the hardware that we ship by the end of June will come in over the next 12-24 months. Our outlook for 2023, I know I said this before, but I think it bears repeating. Particularly for anyone who's new to the story, I wanna just kind of remind everyone that the company's achieved two of the most challenging milestones for any startup, which we certainly were when we launched the company and started working with clients and patients in 2017, 2018. we've been able to go from zero to $1 million in revenue, and then from $1 million to $10 million. Last year, we did over $12 million in revenue last calendar year. These two phases of growth are really transformative for companies. They require dramatic changes to operations, and they test every assumption in the business model. As you've seen, some of those assumptions we realized were not entirely valid and, therefore needed to be adjusted. We've demonstrated, I think, as a company, our ability to learn and adapt during some of these really challenging phases where growth is accelerating tremendously and, your business model assumptions are really trial by fire, very much tested. We've been able to adapt, and I think, you know, as a result, we're seeing some really significant changes in terms of some of the key metrics like adherence and collections. As a result, I think we've set ourselves up very nicely to have a really breakout year this calendar year. Again, just to reiterate, at this point, many of our sales and many of our new clients come to us through referrals from existing customers. We clearly have a product that works. We will start to share some of those testimonials in future webinars. We've gotten a lot of wonderful testimonials from our clients. We generally use those with other prospective clients. For the most part, testimonials are used really in business development. They're not on our website, which is more investor-facing, but they are used very extensively in our business development and sales process to get new clients on board if when they start the due diligence process. If we get an inbound lead, they often wanna hear not just from the friend that they've heard from, but see some other testimonials from other clients who are using the product and maybe make contact with some of those clients. Having those testimonials is really instrumental to the business, and we certainly have a lot of them. A lot of our clients have really been amazing advocates for us, talking to prospective customers during the due diligence phase, which has really helped us get to this point where our sales have really become kind of autocatalytic. We're certainly attracting a much larger scale client than we did when we started out in 2017 and 2018, which is kind of a standard metric in healthcare. If you are going to be a successful company, you need to see that evolution from starting with individual physician practices or home health agency or other smaller customers into the larger customers and gaining credibility there. It's a very good sign for us that we've achieved that milestone and we have that credibility with those larger, more mature organizations. Our outlook financially for 2023, we do not need to raise capital or take on debt to fund operations. We get a lot of questions about either taking on debt or capital, and I think I address that in a little bit more detail when we get into the shareholder FAQs, but that's not part of the plan. We still expect to list to the Nasdaq in the second half of 2023. We are working hard to achieve the revenue milestones and certainly the adherence and collection milestones that will allow us to proceed with that, I think, significant change for the company, but a very positive change, future change. We still expect to initiate a share buyback program in 2023. As evidenced by the contracts that we've announced with that large physician network in Florida, the three skilled nursing facility networks that are in Florida, California, and Pennsylvania, and the large healthcare system that we've announced. We are clearly now able to attract those larger clients. They have not only significant revenue potential, but also because they're more mature organizations, they tend to make collections a little bit easier. They also help out a lot with the adherence piece. That's a very positive change for us. We expect our attraction with the larger clients to continue to accelerate in 2023 and beyond. Into the shareholder FAQs. One of the questions we got, I'm not gonna go into great details about the underlying changes because they're not extremely relevant since they don't actually affect us. One question we've gotten a few times lately is, will the recent changes to Medicaid that end the pandemic-related allowance for continuous enrollment affect Reliq? All that continuous enrollment refers to is if a patient's on an RPM platform, previously before the pandemic, the clinician had to write new orders periodically saying, you know, "This patient still needs RPM services." During the pandemic, those patients did not require those renewal orders from the physician. They were continuously enrolled. That's changed now that they're ending a lot of the pandemic-related measures. It's not really relevant to Reliq because virtually all of our patients are either Medicare, that's the vast majority, or they have dual coverage, so they're covered by both Medicare and Medicaid. Medicare covers everyone over 65 in the States. Medicaid covers everyone who lives below the poverty level, which is quite low in the U.S., and people with certain disabilities. For the most part, our patients who are on Medicaid are also on Medicare, and so we bill through Medicare, and any Medicaid changes don't really impact us. Any Medicaid-only patients that we've had, and those would typically be patients that we've had on the platform for a very long time because we did start out with Medicaid patients. Those patients have already been part of that process, the pre-pandemic process of their doctor will automatically send in renewal orders periodically as needed. We'll continue with that process for those patients. It's a very minor thing, and we can set automated alerts for the clinicians to remind them if there is a renewal notice that needs to be sent in. Bottom line, there's no impact to Reliq from those changes. Another question we get a lot, how long do we retain patients? Are they on just for a few months, and then they drop off? What's our overall attrition rate? Patients that are onboarded to the iUGO platform are typically older, so over 65, and therefore are Medicare patients, and they have multiple complex chronic diseases. Generally, when a clinician adds a patient to our platform, the expectation is that the patient will be on for the remainder of their life or at least until they enter hospice care, at which point they're no longer eligible for Medicare/Medicaid-covered preventive services for obvious reasons, since hospice is end-of-life care. Typically, we'll have patients on the platform for years to decades. On average, we've seen that about 5% of all the patients on the platform will die as a result of their underlying health conditions in any given year. At the same time, each client that we have will add an additional 13% in terms of new patient numbers to our platform because the population is aging and growing. Also as clinicians get a little more comfortable, you'll get some new patients from that. Our net gain is typically about 8% per year for all existing clients. Once we've got you as a client, there'll be an overall, I suppose you could call it a negative attrition rate. There's no actual net loss. There's a net gain of 8% in terms of our total patient numbers for each client every year. Why does Reliq not provide services in Canada? Not for lack of trying. We certainly had lots of communication with government and a lot of support from government, or at least a lot of support, vocal support from government. Ultimately, you know, when the rubber hits the road, the fact is that in Canada, we don't have billing codes that support remote patient monitoring or chronic care management, behavioral health integration, or really any of the modules that we have. There's no incentive for clinicians in Canada to provide these services to their patients. They don't have any extra time they wanna devote to something new, and if they're not gonna be paid for it just doesn't make sense. I certainly understand that philosophy and can't argue with that. Canada is not an ideal marketplace for us at the moment. Fortunately, the U.S. has 57 million Medicare and Medicaid patients who are eligible to receive services that are delivered through iUGO Care. We have an enormous total addressable market in the U.S., and don't need to be looking outside of the U.S. for additional business. Obviously, if anything changed in Canada, we would be very happy to provide these services at home, including to my own parents, frankly. Why did it take so long to address the adherence issue? I think something that's really important to remember, just a kind of a general point, is that everything moves very slowly in healthcare. Healthcare customers are not used to fast pace, in terms of software or administration or anything other than sort of the actual clinical processes, and even there, depending on what the field of practice is. You know, an ER doctor is certainly used to working at a very aggressive pace, but, you know, someone who's referring patients and waiting for specialists to get back to them, the pace may not be as frenetic. Certainly, they're saving the bulk of their energy, our healthcare clients, for the clinical focus, the patients, which is as it should be. Typically, when we deploy with a client of any size in healthcare, any kind of software, they deploy in stages. Clients like to get comfortable before they put all of their patients or even all of their clinicians. If it's a, for example, an electronic medical record that's rolling out in a hospital, that'll roll out kind of ward by ward. It's not going to go to the whole hospital all at once. It's always done in phases. Typically, that involves starting with smaller numbers of patients per client. As a result of that, it's really hard to see trends until you've gotten past that initial phase, and they start to add larger number of patients. At that point, you have sort of a statistically significant population or sample size where, you know, trends become much more obvious. Once the adherence issue was identified, which did take, you know, quite a few months because it just takes that long for patients to get onboarded and for us to start seeing the adherence rates from clients and recognize that this isn't a one-off, this is an ongoing issue and an actual confirmed trend. Once we identified the adherence issue and went to clients to discuss it with them, they still believed, for the most part, that they were the best ones to take on responsibility or to own that adherence management piece, and they wanted a chance to improve on their own. Many of the clinicians cited the Omicron wave as the root cause of the adherence issues in the first half of 2022. We really had to give our clients that opportunity to manage adherence and to see how they would do. Of course, you know, we were very focused all through 2021 and 2022 on just really getting more patients, more clients, more contracts so that we could establish ourselves as the market dominator in this space, which I think we've done very successfully. The result of that work is that we now are able to attract these much larger clients who are going to contribute very significantly to Reliq's bottom line. I think that was important work. It's also important to remember that we did get something that was very valuable out of clients, even when they were not getting patients fully adherent and were therefore not generating the revenue we had originally anticipated during the timeframe we'd anticipated. During that period, with the patients that they did have onboarded, even if they weren't adherent, so they hadn't reached that 16 days out of every month adherence threshold, but patients did collect data at least some days. That clinical data that was collected is something that we've been able to use with these larger clients when they're doing due diligence to show them that there is an impact of using the platform. And certainly the fully adherent patients, that data is even more compelling. We did get extremely valuable data out of our clients and patients in 2021 and 2022. And that's really built the foundation on which, you know, we can then build significant growth and revenue. You know, I don't want anyone to sort of walk away thinking we didn't get anything of value out of clients in 2022, and certainly that's not the case. That's fundamentally going to change, as you've already seen a little bit in 2023, but certainly going forward, there'll be very significant changes around adherence and collections. Hopefully that will allay any worries that anyone had on that front. After we provided clients with several months to improve, we concluded that despite their best efforts, really their focus was on patient care as it should be. That meant that we definitely needed to take over responsibility for managing adherence. We sat down and developed a plan that would allow us to use our existing resources and all the tools at our disposal and start to actually take over adherence from all of the clients and aggressively manage that. That plan was implemented January 1st, 2023, as you know. Again, takes a little bit of time to get clients on board and agreeing to provide the permissions, necessary permissions and then it takes us a little while to reach out to all of the clients who or patients rather, who had been kind of neglected by a clinician in terms of getting them onboarded onto the platform and actually using it. We've now really picked up a lot of momentum and I think going forward, you'll see the results of that as the adherence just continues to improve. What are the cost savings for larger organizations? Clients benefit from implementing our solutions because they generate new revenue. It's a brand-new revenue stream. They also have a couple of other benefits. There's the sort of softer benefit of improving quality metrics. Things like reducing hospitalizations, improving patient satisfaction, improving health outcomes, but also reducing costs. Particularly for the large groups, for example, for a skilled nursing facility, the cost savings are around avoiding a clawback of up to 6% of total revenue by CMS. If you have a higher than average rate of readmission, which, if you look at the statistics around hospitals in Florida, for example, I think it's 97% of them have sufficiently high rates of readmission that they're subject to the full penalties from CMS. That's a pretty significant chunk of your revenue that will, in the following year, be held back by Medicare. You're just not going to get that part of your revenue. For organizations, particularly skilled nursing facilities, who operate at very narrow margins, that's a really big piece for them to avoid. If they're able to preserve that revenue and not lose it to penalties, that has a tremendous impact on their bottom line. Savings will vary depending on the organization and the care setting, but the large networks can save millions of dollars annually by deploying our platform. It does have a really significant impact on their finances. How does the use of AI or artificial intelligence impact Reliq's business? Our platform can leverage AI in a large number of ways. It really depends on the client's needs. We've always been very client need driven. That's why we've developed multiple different modules within the platform when new billing codes were introduced. AI used with our platform, or delivered, you know, from our platform, can allow clients to do things like identify patients who are at risk of falls or cardiac or respiratory events, depression, so they can intervene early before you end up with a health crisis. To be honest, clients aren't particularly motivated to use AI at this point. There isn't really a significant incentive, you know, financially to implement AI at this point. Not to say it's not coming. It's certainly something that our platform supports, and our platform is very capable of delivering all kinds of artificial intelligence based on client needs. It's just not a market demand right now. Ultimately, I could certainly see ChatGPT or a similar platform being used to provide automated chats with some of our elderly patients to provide that intellectual stimulation and some virtual companionship when they're, you know, alone at home. I've said that we won't use that technology until it's more predictable, and I think anyone who's very familiar with artificial intelligence will understand that what I'm referring to is things like the ChatGPT-generated Seinfeld web series that devolved into essentially a number of hate crimes and, you know, some of the other artificial intelligence that gets to a point where it just suddenly becomes quite wildly racist and bigoted. That's not something we wanna expose our patients to at this point or ever. We wanna wait until that technology is a little more mature and a little more predictable. I think there are a lot of applications where it could be of use going forward once clients are a little more comfortable. How many skilled nursing facility patients will continue with services after the first 30 days post-discharge? The majority. I mean, we're still sort of early days, so I can't put a hard figure around that, but I would say 70%-80% minimum will continue to receive virtual care through our platform after the first 30 days post-discharge. Are patients that are in a skilled nursing facility for rehabilitation after, say, a hip replacement or other orthopedic surgery eligible for Reliq's services? Yes, they are. The reason for that is that the majority of these patients also have other, what we call comorbidities or coexisting conditions like high blood pressure and diabetes. Both high blood pressure and diabetes significantly increase your risk of delayed healing, of infection, and of complications post-op, like blood clots or cardiac events like a myocardial infarction, pulmonary embolism. Obviously, those are primarily clot-related. Managing their conditions in the home post-surgery does have a really dramatic impact on healing and return to more-mobility. The platform can be used in a variety of ways. Many of them are the sort of standard ways that you're familiar with, like remote patient monitoring. It can also be used to do things like a virtual assessment, so just using your webcam or a webcam, an assessment of the incision site to see if there are any signs of infection. That's really important in diabetic patients in particular. To track wound healing and just make sure that everything is progressing as expected, which can really have a very positive effect on reducing complications that are resulting from infections, which can be, you know, anything from needing debridement of the surgical site all the way up to sepsis and possible death. The platform can also be used to monitor medication use, which can be really important in orthopedic patients, particularly when you have an elderly patient who's on a lot of different medications. If you're adding in a pain medicine, that can have some, you know, cognitive and functional impact. Making sure that patient isn't taking too much of that medication or becoming too dependent on that medication, can really have a positive effect on the patient's sort of long-term prognosis. That's something that is a tool that I think clinicians find very valuable. The platform certainly has applications beyond just kind of standard chronic disease. What is adherence versus compliance? Compliance is a broad term that covers, you know, essentially a patient obeying their physician's instructions. Remembering to monitor their vitals, take their medications as prescribed, perform prescribed rehabilitation exercises, maybe make some lifestyle changes. It's really quite a broad umbrella term that just means, you know, sort of doing what your physician has told you to do. We use the adherence term to refer specifically to whether or not a patient is collecting their vital signs at least 16 days out of every month. If they are, then their clinician is eligible to deliver services using the iUGO Care platform to that patient, and they can bill Medicare and Medicaid and get paid for it. Therefore, we are able to deliver the services through the platform on behalf of the clinician and get paid for it. If the patient is not adherent, that means they're collecting their vital signs less than 16 days out of every month, the clinician can't bill, and we can't bill. Adherence has a very narrow definition the way that we're using it, and it's specifically really around whether or not there's billable activity there. Do we generate additional revenue for managing adherence? Yes, if we take over the management of adherence from a client, we are able to generate new incremental revenue for taking on that responsibility, essentially contacting patients for the first time to say, you know, "You've had this device for nine months. We can see your clinician wasn't able to kind of follow- up with you to get you started using it, but here's how you're gonna use it, and here's how the program works." Or even just a follow-up call to say, "Oh, I see you've only collected, you know, readings every second or fourth day or something over the last week or two, and we just wanna make sure that ramps up over the rest of the month." Those phone calls are billable activities under the chronic care management billing code. We are able to generate incremental new revenue for ourselves and for the clinician when we are active in care management or adherence management, excuse me. How are the skilled nursing deployments going so far? They're going very well. Again, it's early days, but I've been very pleased, with the clinical output, so the outcomes. To date, none of the patients enrolled in our transitional care management program, which is the post-discharge program, have needed to be readmitted to a hospital or a skilled nursing facility. The average rate of readmission for this population is well over 25%. That's a big drop, a significant decrease, which translates, as you now know, to a reduction in penalties or potentially elimination of penalties for that skilled nursing facility in addition to that additional revenue related to using the program. That's a very positive clinical metric. As we previously disclosed when we made our first announcement about the first 40 skilled nursing facilities that were part of that Florida network, they were live by the end of March, so last month. Now they're ramping up their rate of patient onboarding at each facility, and we are certainly adding other facilities as referenced in the other press releases. You know, the bottom line is that by the end of this calendar year, we expect to be adding over 20,000 skilled nursing facility patients per month to the platform. It'll be a really significant component of our revenue by the end of this year. We really like the skilled nursing facilities. They're excellent partners for the company. They train the patients on the devices while they're still in the facility, while they're still resident. So they already know how to use those devices before they ever go home, which really helps to ensure a high level of adherence post-discharge. In a lot of ways, that makes our life easier. Certainly these larger organizations that have, you know, accounting departments are much easier to manage from a collections perspective. On the, you know, date that something is due according to the vendor's terms, bills get paid, which is really wonderful for us. Traditionally with the individual physician practices and home health agencies, and this is not unique to Reliq, but those clients tend to need a bit more chasing than these larger groups do. Does the company expect to take on debt to finance growth? No, we do not. We expect to have sufficient free cash flow in the second half of this calendar year to implement a share buyback program. We wouldn't do that, you know, if we were taking on debt to otherwise finance operations. We don't anticipate needing to bring in any external capital in the form of debt or equity to fund operations or to fuel the significant anticipated growth that we have. Now that collections have really started to ramp up and we are gaining this amount of momentum, it's been a wonderful past few weeks as to see that ramp really taking off, in terms of, you know, collections, payments coming in. Certainly that just reaffirms our commitment to not taking on additional dilution. I've thrown some final comments in here. It's not really a shareholder FAQ, but just to kind of try to tie it all together. I wanna reiterate that in January of this year, we introduced a number of key changes to our business model and to our operational processes in order to address issues around adherence and collections. My team or Reliq team members implemented these changes at the beginning of last quarter and really did gain a lot of traction by the end of March. We were very much seeing the changes that we wanted to see by the end of March. We expect to fully reach our adherence and collection targets by the end of the current fiscal year, so end of June 2023. At which point, I think we'll be in a much better position to provide more granular forecasts and reporting for the remainder of 2023 and beyond. At the moment, there's still a lot of moving parts, and we still are, you know, collecting a relatively small pool of data on the impact of the changes that we've made, but certainly all indicators and all trends are extremely positive, in terms of improvements around adherence and collections. But I think we'll be able to provide a lot more detail in reporting and everything by the end of the fiscal year, once we have just a little more time under our belts where clients are behaving the way we want them to. The company continues to secure new contracts with increasingly large clients. Most recently, and I do wanna revisit this even though it was released in a press release, but signing that large healthcare system is a really significant step forward for the company. They're the largest client we've signed to date. They have 1,200 care settings, including primary care practices, skilled nursing facilities, hospice and home health agencies, and hospitals. They had over 10 million patient encounters in 2022. This is a real indication of the credibility that the company has gained in the healthcare space that we're now able to really play with the big guys and attract these very large clients. I think with the changes that we've made around adherence and collections, we have positioned the company so that 2023 should be a very successful year. Certainly we expect that success to continue beyond 2023. I think we've positioned ourselves for very significant growth this year and subsequent years, and also, you know, cash in the bank to match that. Overall, you know, I think we've certainly had to ask our shareholders to be patient many times, we appreciate that patience. I think the changes that we've made have had the impact that we were hoping. We look forward to providing our shareholders with continued updates, and to getting into more detail, a greater level of detail with those progress reports and forecasts going forward as we have more data to share. Future webinar dates. The quarterly financials for the quarter ended March 31st are due to be filed on or before May 30th, and so we will schedule the quarterly webinar likely May 31st. Certainly if it's going to be any earlier, we'd issue a news release to let you know. We plan to hold a webinar in mid-July. The exact date is still to be determined, but we want to provide a preliminary update on the fiscal year which ends June 30th. Certainly, it's going to take until October to get through the audit with KPMG and actually be able to publish those financials, file them, but we will provide at least an informal update in July. Closer to mid-July, we'll provide an exact date for that webinar. Thank you very much for joining us today. The recording of this webinar will be posted on our website later today. Just please give our web team a chance to process it and get it uploaded, but it will be available later today. Thank you for joining us. Take care.